Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Sébastien Perreault, MD, FRCPC, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada, presents the Canadian consensus for biomarker testing and treatment of TRK fusion cancer in pediatric patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Sébastien Perreault, MD, FRCPC has received an advisory board role and conference support from Bayer, conference support from Eisai, and research support from Novartis.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.